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CORRESPONDENCE
Re. ‘Provision of Vascular Surgery in England in 2012’
Grewal et al.1 rightly claim the importance of assessing the
state of vascular surgery in England at this time of signiﬁ-
cant change and development of specialty status. However,
there are some potentially serious inaccuracies. In the
‘Results’ section the authors say 167 out of 169 Trusts
(98.8%) replied, but go on to say that four Trusts did not
reply. This appears to be inconsistent.
They also state that only 80 of the 167 Trusts who
responded to the Freedom of Information (FOI) requests
provide vascular surgery services. Furthermore, the two
ﬁgures in the article appear to have red ﬂags, presumably
representing the hub (Figure 1) and non-hub (Figure 2)
vascular providers. Although the text records 48 hub hos-
pitals and 32 non-hub hospitals, the ﬁgures seem to
represent different numbers of each, although Norfolk and
Cornwall are not included in the ﬁgures.
The text does not provide a list of Trusts in each category,
but some sites are named in the ﬁgures, but are indicated
as neither hub nor non-hub hospitals.When the FOI request
responses for Durham and Darlington NHS Trust, Mid
Yorkshire Hospitals NHS Trust (Wakeﬁeld), Chesterﬁeld and
Derby were reviewed they all said they provide vascular
services yet are not clearly represented in the article.
The authors may wish to carefully review the source of
their data, available at whatdotheyknow.com because there
is a risk that they have misrepresented the responses,
making their conclusions about the provision of vascular
surgery inaccurate.
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Re. ‘Re. Provision of Vascular Surgery in England in 2012’
We welcome the comments by Mr Curley regarding our
paper on provision of vascular surgery in England in 2012.1
There is a typographical error and it should indeed state
that only two trusts did not reply.The questionnaire represents a snapshot of vascular
services in relation to early 2012. The situation may have
changed by now. The aim of the paper was to assess in
the most objective way and directly from the Trusts how
the centralisation process was developing. The maps
were intended as a visual representation of the more
detailed tables, especially for readers unfamiliar with
English cities.
Addressing the speciﬁc trusts mentioned, the data is
available in the tables provided within the paper. Royal
Derby Hospitals NHS Foundation Trust and County Durham
and Darlington NHS Foundation Trust are documented in
Table 1 as hub hospitals. Within the West Yorkshire Central
County, Mid Yorkshire Hospitals NHS Trust is documented as
centralising with Leeds Teaching Hospitals NHS Trust, but
continuing to provide arterial surgery at the Mid Yorkshire
site. Chesterﬁeld have stated that they are looking to
centralise with Derby and as such were not mentioned
separately.
REFERENCE
1 Grewal P, Davis M, Hamilton G. Provision of vascular surgery in
England in 2012. Eur J Vasc Endovasc Surg 2013;45(1):65e75.
P. Grewal*, M. Davis
Queen Alexandra Hospital, Portsmouth, UK
G. Hamilton
Royal Free NHS Foundation Trust, London, UK
*Corresponding author.
Email-addresses: perbinder.grewal@porthosp.nhs.uk,
perbinder@yahoo.com (P. Grewal)
Available online 7 May 2013
 2013 European Society for Vascular Surgery. Published by
Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2013.04.010
DOI of original article: http://dx.doi.org/10.1016/
j.ejvs.2013.03.026
Re. ‘Cost-effectiveness of Vascular Access for
Haemodialyis: Arteriovenous Fistulas Versus
Arteriovenous Grafts’
We read with interest the paper of Leermakers et al.1 We
propose that rather than comparing the cost-effectiveness
of arteriovenous ﬁstulas (AVF) and arteriovenous grafts
(AVG) the real question is: What is the most cost-effective
way to provide safe renal replacement therapy (RRT) to
patients with end-stage renal disease (ESRD)?
Infection is undoubtedly one of the greatest threats to
patient well-being while receiving RRT, and poses a signiﬁ-
cant cost to healthcare providers.
fA retrospective audit was carried out over an 18-month
period, comparing bacteraemia rates for each renal re-
placement modality (n ¼ 1997). Results are expressed as
bacteraemia episodes per 1000 patient days and estimated
annual costs in brackets (assuming an average cost of line
sepsis of £10,000):2,3 haemodialysis (HD) via a central
venous catheter (CVC) (n ¼ 403) 1.93 (£33,295.50); HD via
an AVF (n ¼ 670), 0.23 (£25,802.50); peritoneal dialysis
(n ¼ 157) 0.09 (£19,414.50) and renal transplantation
(n ¼ 1091) 0.03 (£22,109.50 in the ﬁrst year and £5109.50
for each subsequent year). Switching from CVC to AVF
(n ¼ 90) reduced the bacteraemia rate from 1.96 to 0.55
(p ¼ 0.01) and to transplant (n ¼ 38) from 2.72 to 0.73
(p ¼ 0.06).
Leermakers et al. report the median life-span of an
AVF and AVG to be 28.5 and 25.5 months, respectively,
while renal transplantation has a median survival of
13.5 years.1 These ﬁgures support an integrated RRT
strategy, including maximisation of opportunities for
renal transplantation as a cost-effective means to
minimise infection rates in patients with ESRD. In
particular, live donor renal transplantation should be
considered wherever possible as a means to reduce bac-
teraemia rates in patients currently dialysing via CVC rather
than switching to AVF/AVG, and organ allocation policies
based on clinical need (including vascular access status)
may be beneﬁcial.
REFERENCES
1 Leermakers JJ, Bode AS, Vaidya A, van der Sande FM, Evers SM,
Tordoir JH. Cost-effectiveness of vascular access for haemodial-
ysis: arteriovenous ﬁstulas versus arteriovenous grafts. Eur J Vas
Endovasc Surg 2013;45:84e92.
2 Department of Health. 2010e11 Reference costs. Available
at: www.dh.gov.uk/en/PublicationsandStatistics/Publications/
PublicationsPolicyandGuidance/DH_131140 [accessed 12.04.13].
3 NHS Blood and Transplant. Statistics. Available at: www.
organdonation.nhs.uk/statistics [accessed 12.04.13].
M. McDermott*
University of Glasgow, Glasgow, UK
E. Aitken, C. Geddes, M. Clancy
Western Inﬁrmary, Glasgow, UK
*Corresponding author.
Email-address: 0900527M@student.gla.ac.uk (M.
McDermott)
Available online 1 May 2013
 2013 European Society for Vascular Surgery. Published by
Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2013.03.031
DOI of original article: http://dx.doi.org/10.1016/
j.ejvs.2012.10.012
150 European Journal oRe. ‘Re. ‘Cost-effectiveness of Vascular Access for
Haemodialyis: Arteriovenous Fistulas Versus
Arteriovenous Grafts”
McDermott et al. recognize infections as the most serious and
common complication of vascular access (VA) for hemodialysis
(HD) or peritoneal dialysis (PD) treatment, with subsequently
higher costs for these renal replacement modalities compared
with renal transplantation.1 This may be true for patients with
HD through central vein catheters, but certainly not for patients
receiving either PD or HD through arteriovenous ﬁstulae (AVF)
or arteriovenous grafts (AVG). Several publications have shown
similar outcome in terms of morbidity, hospital admission and
deathas a result of infectious complications inpatients onPDor
HD with an AVF or AVG as vascular access.2,3
The purpose of our study was to compare all costs
necessary to establish and maintain VA through an AVF or
AVG. This not only includes costs for treatment of infection,
but also in particular costs for access maintenance and
revision, like endovascular and/or surgical interventions, to
establish long-term patency.4
We do agree that renal transplantation is the ultimate goal
to treat young patients, in particular, with chronic renal fail-
ure and as in many centers, living-related kidney trans-
plantation is in our center a well-established method for
these patient groups. But one should keep in mind that
nowadays most patients in HD programs are very old with
multiple comorbidities, with a contra indication for renal
transplantation. These old patients, who are usually not on
thewaiting list for transplantation,may certainly beneﬁt from
an AVF, which, in addition, incurs lower healthcare costs to
main access patency in comparison with the use of AVGs.
Comparing renal transplantationwith theoutcomeofAVFand
AVG as HD vascular access, was not the purpose of our study.
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